目的：分析我国重点短缺药品品种，探讨供应保障措施，为缓解药品短缺和实施相关政策提供参考。方法：检索我国政府网站，收集整理短缺药品监测报告，从监测哨点角度、省级监测平台角度和短缺药品来源角度，总结归纳出我国重点短缺药品品种，分析其短缺原因，提出措施建议。结果与结论：我国短缺药品中，国产药品、化学药品占比较高，抗肿瘤药短缺问题突出，基本药物目录、医保目录内品种占比高。为做好短缺药品综合供应保障，应在落实已有政策的基础上，学习国外管理经验，着力解决重点短缺药品、完善监测平台、发挥政策引导作用，加强企业社会责任意识，做好数据挖掘和信息公开，多举措保障药品的可及性。
Objective:To analyze the varieties of key drugs in shortage and discuss the supply safeguard measures in order to provide reference for alleviating the drug shortage and implementing relevant policies. Methods:Government websites were retrieved and monitoring reports about the drugs in shortage were collected and classified. The varieties of key drugs in shortage were further summarized from the perspective of sentinel surveillance, provincial monitoring platform and the source of the drug shortage. Meanwhile, the reasons for the shortage were analyzed and suggestions for supply were put forward. Results and Conclusion:Among the drugs in shortage in our country, the proportion of chemical drugs and domestic drugs was high, and the shortage of anti-tumor drugs was prominent. Most of the key drugs in shortage were included in the catalogue of essential medicines and medical insurance directory. In order to ensure the comprehensive supply of drugs in shortage, we should learn from foreign management experience on the basis of implementing existing policies, put emphasis on solving the problem of the key drugs in shortage, improve monitoring platforms, play the role of policy guidance, strengthen the social responsibility awareness of enterprises, and deepen the data mining and information disclosure. In short, multiple measures should be used to ensure the availability of drugs.
[1] 姚强,罗飞,何路洋,等. 药品可及性视角下国家基本药物制度实施效果评价[J]. 中国医院管理,2014,34(3):60-62.
[2] 张伶俐,陈哲,曾力楠,等. 全球短缺药品监测制度的循证评价[J]. 中国药房,2017,28(34):4753-4758.
[3] 武丽娜,方宇,杨才君,等. 我国药品短缺问题研究进展评述[J]. 中国药事,2016,30(5):458-465.
[4] 蔡文芳,杨才君,沈倩,等. 国内外药品短缺问题研究进展[J]. 中国药事,2016,30(12):1190-1199.
[5] 丁发明,王涛. 从药品监管角度初步探索我国药品短缺问题的处置策略[J]. 中国临床药理学杂志,2017,33(23):2511-2514.
[6] 何梦婷,冯国忠,周振,等. 国外药品短缺处理机制的比较及对我国的启示[J]. 中国药事,2017(9):980-983.
[7] FDA. Statement from FDA Commissioner Scott Gottlieb, M.D.,on FDA's Work to Mitigate Shortages of Intravenous Drugs,Shorten Supply Disruptions and Better Predict Vulnerabilities[EB/OL]. (2018-05-31)[2018-06-04] https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609453.htm.
[8] WHO. Meeting report:Technical Definitions of Shortages and Stockouts of Medicines and Vaccines[EB/OL].(2016-10-05)[2018-02-27]. http://www.who.int/medicines/areas/access/WHO_EMP_IAU_2017-03/en/.
[9] 北京市医药集中采购服务中心. 关于公布《北京市药品集中采购短缺药品目录调整制定办法(试行)》的通知[EB/OL]. (2014-07-16)[2018-02-27]. http://www.bjmbc.org.cn/index/xxgk_detail.aspx?record_id=456916.
[10] 国家卫生计生委药物政策与基本药物制度司. 两种短缺药品市场撮合工作顺利完成[EB/OL].(2017-07-13)[2018-02-27]. http://www.moh.gov.cn/yaozs/s7652/201707/050478537afb411bb8e5aae408dcd326.shtml.
[11] 郭冬梅,赵静,何敏媚,等. 对《国家基本药物目录》 (2012版)的解读[J]. 临床药物治疗杂志,2013,11(6):47-51.
[12] 朱剑红,刘志强. 五百余种低价药市场定价[J]. 中国医疗保险,2014,(7):71-71.
[13] FDA. Economic Analysis of the Causes of Drug Shortages[EB/OL]. (2018-05-31)[2018-06-04] https://aspe.hhs.gov/report/economic-analysis-causes-drug-shortages.
[14] 李勇,盛亚楠,赵梦蕊,等. 供应链视角下我国药品短缺原因及供应保障研究[J]. 卫生经济研究,2017, (6):55-59.
[15] 胡安琪,马爱霞,李勇. 生产企业视角下我国药品短缺原因分析[J]. 中国药物评价,2017,34(2):150-152.
[16] 国家卫生计生委药物政策与基本药物制度司. 关于2016年临床必需、用量小、市场供应短缺药品定点生产试点有关事项的通知[EB/OL]. (2017-01-05)[2018-02-27]. http://www.moh.gov.cn/yaozs/s3581/201701/75150182dbb74ca78ce3397d28d51cb8.shtml.
[17] 辽宁省医疗机构药品和医用耗材集中采购工作领导小组办公室. 关于发布辽宁省2017年第1号药品短缺预警预报的通知[EB/OL]. (2017-01-26)[2018-02-27]. http://www.lndoh.gov.cn/wst_sjdwdt/201702/t20170204_2782535.html.
[18] 发改委价格监督检查与反垄断局. 新赛科公司、汉德威公司因原料药价格垄断行为被依法处罚[EB/OL]. (2017-07-31)[2018-02-27]. http://jjs.ndrc.gov.cn/fjgld/201707/t20170731_856432.html.
[19] 工商总局竞争执法局.竞争执法公告2016年12号重庆西南制药二厂有限责任公司垄断行为案[EB/OL].(2016-12-12)[2018-02-27]. http://www.saic.gov.cn/fw/bsdt/gg/jzzf/201612/t20161212_231633.html.
[20] 国家卫生计生委药政司.关于硫酸鱼精蛋白注射液供应短缺的有关情况[EB/OL]. (2016-05-10)[2018-02-27]. http://cdsip.nhfpc.gov.cn/work/show2931.html.
[21] 辽宁省医疗机构药品和医用耗材集中采购工作领导小组办公室. 关于发布辽宁省2016年第1号药品短缺预警预报的通知[EB/OL]. (2016-07-07)[2018-02-27] http://www.lndoh.gov.cn/wst_sjdwdt/201702/t20170204_2782535.html.
[22] 蒋锋,孙静,刘远立. 药品集中采购中相关法律问题的思考[J]. 中国药房,2017,28(18):2449-2451.
[23] 广东省药品交易中心. 关于药品交易中第五批未按合同供货及未及时供货企业的公示[EB/OL].(2017-05-02)[2018-02-27]. http://www.gdmede.com.cn/CMS/Notice/201752/n400013874.aspx.
[24] 浙江省药械采购中心. 关于将部分流感防治药品临时纳入供应紧张药品管理系统的通知(二)[EB/OL]. (2018-01-16)[2018-02-27]. http://www.zjyxcg.cn/HomePage/ShowDetail.aspx?InfoId=2804&type=1&bigtype=.
[25] FDA. Fifth Annual Report on Drug Shortages for Calendar Year 2017[EB/OL].(2018-05-16)[2018-06-04]. https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM610662.pdf.
[26] 国家卫生计生委药物政策与基本药物制度司. 关于改革完善短缺药品供应保障机制的实施意见[EB/OL]. (2017-06-28)[2018-02-27]. http://www.nhfpc.gov.cn/yaozs/s3581/201706/ec2c5910ba4341559e0176e5e237d5e6.shtml.
[27] 张梦倩,冯国忠. 美国药品短缺应对机制及其对我国的启示[J]. 中国药事,2017,31(8):838-842.
[28] FDA. Extended Use Dates Provided by Pfizer to Assist with Emergency Syringe Shortages[EB/OL]. (2018-06-12)[2018-06-15]. https://www.fda.gov/drugs/drugsafety/drugshortages/ucm563360.htm.
[29] FDA. Extension of Shelf Life Provided by Baxter Healthcare Corporation to Assist with IV Solution Shortages[EB/OL]. (2018-05-21)[2018-06-15] https://www.fda.gov/drugs/drugsafety/drugshortages/ucm593084.htm.
